recurrent/metastatic nasopharyngeal carcinoma
Conditions
Interventions
Test group:Gemcitabine + Cisplatin + PD-1 monoclonal antibody + CTL
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: (1) Age =18 years, gender not specified; (2) Patients with initially treated recurrent metastatic nasopharyngeal carcinoma confirmed by pathological tissue and/or clinical examination; (3) Good physical condition: Karnofsky Performance Score (KPS) =70 points; (4) Expected survival =12 weeks; (5) No treatment that may affect efficacy evaluation has been received in the past month; (6) Normal hematopoietic and organ function; (7) Women of childbearing age who need to undergo serum pregnancy testing; patients must test negative in the serum test; (8) Participants voluntarily join this study and sign an informed consent form
Exclusion criteria
Exclusion criteria: (1) Patients currently participating in other clinical trials; (2) Patients who have a history of severe anaphylactic reactions, allergic reactions, or other allergic reactions to chimeric or humanized antibodies or fusion proteins, or who have an allergic constitution; (3) Patients with fever for various reasons, excluding transient fever caused by cell infusion; (4) Patients with active autoimmune diseases or a history of autoimmune diseases or related symptoms requiring systemic corticosteroid or immunosuppressive therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Accuracy of diagnosis;Progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate;Duration of response;Overall survival; | — |
Countries
China
Contacts
Public ContactLei Liu
West China Hospital, Sichuan University
Outcome results
None listed